RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

Introduction: EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients with untreated advanced NSCLC and an EGFR-activating...

Full description

Bibliographic Details
Main Authors: Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:JTO Clinical and Research Reports
Subjects:
Carcinoma
Non–small cell lung
EGFR exon 19 deletion variant
Ramucirumab
VEGFR inhibition
Targeted therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001674

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001674

Similar Items